PGCM
ALDX icon

Prescott Group Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

Prescott Group Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-105,000
Closed -$948K – 158
2019
Q1 		$948K Buy
+105,000
New +$892K 0.19% 98

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Prescott Group Capital Management's ALDX Position: Q2 2019 in Review

Prescott Group Capital Management sold out of Aldeyra Therapeutics (ALDX) in Q2 2019, closing a stake of 105,000 shares — an estimated $948K sold.

Prescott Group Capital Management first reported a position in ALDX in Q1 2019 and held it in 1 quarter. The position peaked at $948K in Q1 2019. 76 funds tracked by Wall St. Rank hold ALDX as of Q2 2019.

  • Prescott Group Capital Management reported no remaining Aldeyra Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Prescott Group Capital Management sold 105,000 Aldeyra Therapeutics shares in Q2 2019, an estimated $948K.
  • Prescott Group Capital Management first reported a position in Aldeyra Therapeutics in Q1 2019 and held it in 1 quarter.
  • Prescott Group Capital Management's Aldeyra Therapeutics position peaked at $948K in Q1 2019.
  • 76 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2019.

Based on Prescott Group Capital Management's 13F filing for Q2 2019, filed 9 Aug 2019.